Tandem Diabetes Care (TNDM) Faces Device Scrutiny and Regulatory Optimism—Is Transparency the Key to Trust?

• In August 2025, Tandem Diabetes Care announced a voluntary medical device correction for select t:slim X2 insulin pumps after disclosing a malfunction that could interrupt insulin delivery, attracting multiple securities law investigations regarding alleged misleading disclosures. This series of events has raised concerns about product reliability and company transparency while drawing increased attention from both regulators and shareholders.
• At the same time, the company was experiencing optimism surrounding FDA clearance for its Control-IQ+ technology, reflecting the ongoing tension between regulatory setbacks and potential advancements in innovation for diabetes management solutions.
• We'll examine how heightened scrutiny over device safety and disclosure practices could affect Tandem Diabetes Care's broader investment narrative going forward.

We've found 18 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Tandem Diabetes Care Investment Narrative Recap

Shareholders in Tandem Diabetes Care are typically betting on the company’s ability to drive recurring revenue growth through innovative diabetes management solutions and expansion in pharmacy and international markets. The recent voluntary device correction and resulting securities law investigations present a material near-term risk, as questions around product safety and company disclosures now compete with new product launches as the primary short-term catalysts for sentiment and performance.

Among the recent developments, the FDA clearance for the t:slim X2 insulin pump with Control-IQ+ technology stands out. While this approval presents an important catalyst for market share expansion and long-term adoption, its immediate impact may be overshadowed by unresolved concerns about device reliability and legal scrutiny tied to the recent correction announcement.

However, investors should also consider how increasing regulatory attention may limit margin improvement and create fresh execution risks...

Read the full narrative on Tandem Diabetes Care (it's free!)

Tandem Diabetes Care is projected to reach $1.2 billion in revenue and $14.4 million in earnings by 2028. This outlook assumes 7.5% annual revenue growth and a $219.9 million improvement in earnings from the current level of -$205.5 million.

Uncover how Tandem Diabetes Care's forecasts yield a $20.76 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Fair value estimates from five Simply Wall St Community members range from US$20.76 to US$51.58 per share. With competition intensifying and legal risk in focus, your view on Tandem’s future could vary widely, explore how others see the opportunity.

Explore 5 other fair value estimates on Tandem Diabetes Care - why the stock might be worth just $20.76!

Build Your Own Tandem Diabetes Care Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com